PLoS ONE (Jan 2013)

Serum and lymphocytic neurotrophins profiles in systemic lupus erythematosus: a case-control study.

  • Anne-Laure Fauchais,
  • Marie-Claude Lise,
  • Pierre Marget,
  • François-Xavier Lapeybie,
  • Holy Bezanahary,
  • Clothilde Martel,
  • Stéphanie Dumonteil,
  • Agnès Sparsa,
  • Fabrice Lalloué,
  • Kim Ly,
  • Marie Essig,
  • Elisabeth Vidal,
  • Marie-Odile Jauberteau

DOI
https://doi.org/10.1371/journal.pone.0079414
Journal volume & issue
Vol. 8, no. 11
p. e79414

Abstract

Read online

BackgroundNeurotrophins play a central role in the development and maintenance of the nervous system. However, neurotrophins can also modulate B and T cell proliferation and activation, especially via autocrine loops. We hypothesized that both serum and lymphocytic neurotrophin levels may be deregulated in systemic Lupus erythematosus (SLE) and may reflect clinical symptoms of the disease.MethodsNeurotrophins in the serum (ELISA tests) and lymphocytes (flow cytometry) were measured in 26 SLE patients and 26 control subjects. Th1 (interferon-γ) and Th2 (IL-10) profiles and serum concentration of BAFF were assessed by ELISA in the SLE and control subjects.FindingsWe have demonstrated that both NGF and BDNF serum levels are higher in SLE patients than healthy controls (p=0.003 and pConclusionThis study demonstrates that serum and B cell levels of both NGF and BDNF are increased in SLE, suggesting that the neurotrophin production pathway is deregulated in this disease. These results must be confirmed in a larger study with naive SLE patients, in order to avoid the potential confounding influence of prior immune-modulating treatments on neurotrophin levels.